Evidence map›Paper›PMID 34638344›Full record

ArticleCancers2021

Prognostic Impact of Serum Free Light Chain Ratio Normalization in Patients with Multiple Myeloma Treated within the GMMG-MM5 Trial.

Eva-Maria Klein, Diana Tichy, Hans J Salwender, Elias K Mai, Jan Duerig, Katja C Weisel, Axel Benner, Uta Bertsch, Mabast Akhavanpoor, Britta Besemer and 17 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancers, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.6field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

27 authors at 16 institutions in 1 country.

Eva-Maria KleinDepartment of Medicine V, Hematology, Oncology and Rheumatology, University of Heidelberg, 69120 Heidelberg, Germany.
Diana TichyDivision of Biostatistics, German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany.
Hans J SalwenderAsklepios Tumorzentrum Hamburg, AK Altona and AK St. Georg, 22763 Hamburg, Germany.
Elias K MaiDepartment of Medicine V, Hematology, Oncology and Rheumatology, University of Heidelberg, 69120 Heidelberg, Germany.ORCID 0000-0002-6226-1252
Jan DuerigDepartment of Hematology, University Clinic Essen, 45147 Essen, Germany.
Katja C WeiselDepartment of Oncology, Hematology and Bone Marrow Transplantation with Section of Pneumology, University Medical Center Hamburg-Eppendorf, 20246 Hamburg, Germany.
Axel BennerDivision of Biostatistics, German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany.
Uta BertschDepartment of Medicine V, Hematology, Oncology and Rheumatology, University of Heidelberg, 69120 Heidelberg, Germany.
Mabast AkhavanpoorDepartment of Medicine V, Hematology, Oncology and Rheumatology, University of Heidelberg, 69120 Heidelberg, Germany.
Britta BesemerDepartment of Hematology, Oncology and Immunology, University Hospital Tübingen, 72076 Tübingen, Germany.
Markus MunderDepartment of Internal Medicine III, University Medical Center Mainz, 55131 Mainz, Germany.
Hans-Walter LindemannDepartment of Hematology and Oncology, Katholisches Krankenhaus Hagen, 58097 Hagen, Germany.
Dirk HoseDepartment of Medicine V, Hematology, Oncology and Rheumatology, University of Heidelberg, 69120 Heidelberg, Germany.
Anja SeckingerDepartment of Medicine V, Hematology, Oncology and Rheumatology, University of Heidelberg, 69120 Heidelberg, Germany.ORCID 0000-0002-2771-712X
Steffen LuntzCoordination Centre for Clinical Trials (KKS) Heidelberg, 69120 Heidelberg, Germany.
Anna JauchInstitute of Human Genetics, University of Heidelberg, 69120 Heidelberg, Germany.
Ahmet ElmaagacliDepartment of Hematology and Oncology, Asklepios Hospital Hamburg St. Georg, 20099 Hamburg, Germany.
Stephan FuhrmannDepartment of Hematology and Oncology, Helios Hospital Berlin Buch, 13125 Berlin, Germany.ORCID 0000-0002-7785-2565
Peter BrossartDepartment of Internal Medicine, Oncology, Hematology, Immuno-Oncology and Rheumatology/Clinical Immunology, University Hospital Bonn, 53127 Bonn, Germany.
Martin GoernerDepartment of Hematology, Oncology and Palliative Care, Klinikum Bielefeld, 33604 Bielefeld, Germany.
Helga BernhardInternal Medicine V, Klinikum Darmstadt, 64283 Darmstadt, Germany.
Marc S RaabDepartment of Medicine V, Hematology, Oncology and Rheumatology, University of Heidelberg, 69120 Heidelberg, Germany.
Igor W BlauMedical Clinic, Charité University Medicine Berlin, 13353 Berlin, Germany.
Mathias HaenelDepartment of Internal Medicine III, Klinikum Chemnitz, 09116 Chemnitz, Germany.
Christof ScheidDepartment of Internal Medicine I, University Hospital Cologne, 50937 Cologne, Germany.
Hartmut GoldschmidtDepartment of Medicine V, Hematology, Oncology and Rheumatology, University of Heidelberg, 69120 Heidelberg, Germany.ORCID 0000-0003-0961-0035
On Behalf Of The German-Speaking Myeloma Multicenter Group Gmmg
Heidelberg University · DEGerman Cancer Research Center · DEAsklepios Klinik Altona · DEAsklepios Klinik St. Georg · DECharité - Universitätsmedizin Berlin · DEEssen University Hospital · DEHelios Hospital Berlin-Buch · DEJohannes Gutenberg University Mainz · DEKatholisches Krankenhaus St. Johann Nepomuk · DEKlinikum Bielefeld · DEKlinikum Chemnitz · DEKlinikum Darmstadt · DEUniversität Hamburg · DEUniversity Children's Hospital Tübingen · DEUniversity Hospital Bonn · DEUniversity Hospital Cologne · DE

Funding

Celgene followsChugai Pharmaceutical followsJanssen-Cilag followsThe Binding Site follows
6 · The paper itself

Abstract

We investigated the prognostic impact of time-dependent serum free light chain ratio (FLCr) normalization in 590 patients with secretory multiple myeloma (MM) during first-line treatment within the German-Speaking Myeloma Multicenter Group MM5 trial. Serum free light chains (sFLC) were assessed by the Freelite test at baseline, after induction, mobilization, autologous blood stem cell transplantation, consolidation and every three months during maintenance or follow up within two years after the start of maintenance. The proportion of patients with a normal or normalized FLCr increased from 3.6% at baseline to 23.2% after induction and 64.7% after consolidation. The achievement of FLCr normalization at any one time before the start of maintenance was associated with significantly prolonged progression-free survival (PFS) (

Indexed as

immune reconstitutionmultiple myelomaprognostic factorsserum free light chain ratio normalizationtime-dependent analysis

Identifiers

PMID34638344
PMCPMC8507729
OpenAlexW3203138115

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.